Status:
RECRUITING
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
Lead Sponsor:
Sirtsei Pharmaceuticals, Inc.
Conditions:
Major Depressive Disorder
Depression
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with majo...
Eligibility Criteria
Inclusion
- Key
- In generally good health
- Body mass index (BMI) between 18.0 and 40.0 kg/m2
- Willing to comply with the requirements of the study
- For participants with depression: must meet study criteria for moderate to severe major depressive disorder
- Key
Exclusion
- Female who is pregnant or breastfeeding.
- Clinically significant health condition or clinically significant abnormal results on screening health tests
- For participants with depression: presence of exclusionary study criteria for co-morbid psychiatric conditions or medication history.
Key Trial Info
Start Date :
August 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06570369
Start Date
August 22 2024
End Date
February 1 2026
Last Update
December 30 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CenExel CNS
Garden Grove, California, United States, 92845
2
Alivation Research
Lincoln, Nebraska, United States, 68526